Last reviewed · How we verify
GRC 27864
At a glance
| Generic name | GRC 27864 |
|---|---|
| Sponsor | Glenmark Pharmaceuticals Ltd. India |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- To Evaluate Safety, Tolerability and Pharmacokinetics of GRC 27864 in Healthy Subjects and Elderly Healthy Subjects (PHASE1)
- GRC 27864 First in Man, Single Ascending Dose Study in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GRC 27864 CI brief — competitive landscape report
- GRC 27864 updates RSS · CI watch RSS
- Glenmark Pharmaceuticals Ltd. India portfolio CI